Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET

Company Participants

Kate Rausch - Head, Investor Relations

Paul Bolno - President & Chief Executive Officer

Anne-Marie Li-Kwai-Cheung - Chief Development Officer

Kyle Moran - Chief Financial Officer

Conference Call Participants

Salim Syed - Mizuho

Joon Lee - Truist Securities

Mani Foroohar - SVB Securities

Operator

Good morning, and welcome to the Wave Life Sciences’ Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast.

I will now turn the call over to Kate Rausch, VP of Investor Relations and Corporate Affairs at Wave Life Sciences. Please go ahead.

Kate Rausch

Thank you, operator. Good morning and thank you for joining us today to discuss our recent business progress and review Wave's third quarter 2022 financial results.

Joining me on the room today are Dr. Paul Bolno, President and Chief Executive Officer; Anne-Marie Li-Kwai-Cheung, Chief Development Officer; and Kyle Moran, Chief Financial Officer.

The press release issued this morning and slide presentation to accompany this webcast are available in the Investors Section of our website www.wavelifesciences.com.

Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in the forward- looking statements. The factors that could cause actual results to differ are discussed in the press release issued today, and in our SEC filings, including our annual report on Form 10-k for the year ended December 31, 2021. And our quarterly report on Form 10-Q for the quarter ended September 30, 2022. We undertake no obligation to update or revise any forward-looking statements for any reason.

And now I’d like to turn the call over to Paul. Paul?

Paul Bolno

Thanks, Kate. Good morning. And thank you all for joining us. I will start today's call with some recent highlights and then introduce our Chief Development Officer, Anne-Marie Li-Kwai-Cheung. Ann-Marie will provide updates on our most advanced therapeutic program. And finally, Kyle will discuss our financials.

2022 has been a pivotal year for Wave. At the start of this year, we said, we would deliver data updates from three separate clinical trials as well as advance an entirely new modality through candidate nomination. To date, we have delivered the first two clinical data updates, including results from our ongoing C9-ALS FTD study showing potent and durable target engagement with WVE-004 and most recently, the first clinical data from our SELECT-HD trial for Huntington's disease, indicating allele selective target engagement with WVE-003.